Clinical trials
Retinal Diseases trials with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
68 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 6 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 6 |
| 2020 | 4 |
| 2021 | 6 |
| 2022 | 6 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 32 |
| Recruiting | 10 |
| Unknown status | 10 |
| Terminated | 7 |
| Withdrawn | 5 |
| Not yet recruiting | 2 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Optos, PLC | 6 |
| Duke University | 5 |
| Benha University | 2 |
| Center for Eye Research Australia | 2 |
| LKC Technologies, Inc. | 2 |
| MD Stem Cells | 2 |
| Adiyaman University | 1 |
| Aga Khan University | 1 |
| Akdeniz University | 1 |
| Centervue SpA | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Retinal Diseases | 68 |
| Eye Diseases | 13 |
| Glaucoma | 8 |
| Macular Degeneration | 8 |
| Diabetes Mellitus | 6 |
| Diabetic Retinopathy | 6 |
| Optic Nerve Diseases | 6 |
| Retinal Degeneration | 5 |
| Blindness | 4 |
| Retinal Dystrophies | 4 |
Trials
Showing 51 to 68 of 68. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.